Swelling of the nasal mucosa in colds, pollinosis; rhinitis (vasomotor, allergic); acute sinusitis; otitis media; diagnostics and surgical interventions in the nasal passages to reduce swelling.
active substance: xylometazoline;
1 ml of solution contains xylometazoline hydrochloride in terms of 100% substance, 0.5 mg or 1 mg;
excipients: sodium hydrogen phosphate, dodecahydrate; sodium dihydrogen phosphate, dihydrate; sorbitol (E 420), benzalkonium chloride, disodium edetate; water for injections.
Farmazolin Dosage form
Basic physical and chemical properties: clear, colorless liquid.
Farmazolin Pharmacological group
Means used for diseases of the nasal cavity. Decongestants and other topical preparations for diseases of the nasal cavity. Sympathomimetics, simple drugs. ATX code R01A A07.
Xylometazoline is a sympathomimetic agent that acts on α-adrenergic receptors.
Pharmazolin® causes a narrowing of the nasal blood vessels, reducing the swelling of the nasal mucosa, its paranasal sinuses, thereby improving nasal breathing with nasal congestion and sinuses. The drug is well tolerated, including by patients with sensitive mucous membranes. The drug reduces mucociliary function. Thanks to the moisturizing component (sorbitol), the drug helps with dryness and irritation of the mucous membrane of the nasal passages. Pharmazolin®, nasal drops, has a balanced pH value within the limits of the nasal cavity.
The action of the drug begins a few minutes after application and lasts up to 12 hours. When applied topically, the drug is practically not absorbed, the concentrations of xylometazoline in the blood plasma are so small that they cannot be determined by modern analytical methods.
Symptomatic treatment of nasal congestion with colds, hay fever, other allergic rhinitis, sinusitis.
To facilitate the outflow of secretions in diseases of the paranasal sinuses.
Adjunctive therapy for otitis media (to eliminate swelling of the mucous membrane).
To facilitate rhinoscopy.
Hypersensitivity to xylometazoline or to any other component of the drug, acute coronary diseases, coronary asthma, hyperthyroidism, glaucoma, transphenoidal hypophysectomy and surgery with exposure of the meninges in history, dry rhinitis (rhinitis sicca) or atrophic rhinitis. Concomitant treatment with MAO inhibitors and within 2 weeks after stopping their use.
Interaction with other medicinal products and other forms of interaction
Monoamine oxidase inhibitors (MAO inhibitors): Xylometazoline can potentiate the action of MAO inhibitors and induce a hypertensive crisis. Do not use xylometazoline in patients who have taken or have taken MAO inhibitors within the past two weeks.
Tri- and tetracyclic antidepressants: with the simultaneous use of tri- or tetracyclic antidepressants and sympathomimetics, the sympathomimetic effect of xylometazoline may be enhanced, therefore the simultaneous use of such agents is not recommended.
When used with β-blockers, it may cause bronchial spasm or a decrease in blood pressure.